These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2714846)

  • 21. C4A deficiency and elevated level of immune complexes: the mechanism behind increased susceptibility to systemic lupus erythematosus.
    Traustadottir KH; Sigfusson A; Steinsson K; Erlendsson K
    J Rheumatol; 2002 Nov; 29(11):2359-66. PubMed ID: 12415592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement components, complement activation, and acute phase response in systemic lupus erythematosus.
    Sturfelt G; Sjöholm AG
    Int Arch Allergy Appl Immunol; 1984; 75(1):75-83. PubMed ID: 6086533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the alternative pathway of complement by DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid (Mergetpa).
    von Zabern I; Nolte R
    Complement; 1986; 3(2):97-104. PubMed ID: 3095022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A simple alternative pathway for hemolytic assay of human complement component C3 using methylamine-treated plasma.
    Jessen TE; Barkholt V; Welinder KG
    J Immunol Methods; 1983 May; 60(1-2):89-100. PubMed ID: 6406606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of the alternative pathway of human complement by haemoglobin.
    Wilson WA; Thomas EJ
    Clin Exp Immunol; 1979 Apr; 36(1):140-4. PubMed ID: 111881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.
    Arroyave CM; Wilson MR; Tan EM
    J Immunol; 1976 Mar; 116(3):821-6. PubMed ID: 815434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Equine alternative pathway activation by unsensitized rabbit red blood cells.
    Leid RW; Coley SC; Blanchard DP; Perryman LE
    Vet Immunol Immunopathol; 1985 May; 9(1):71-85. PubMed ID: 4024451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased amounts of C4-containing immune complexes and inefficient activation of C3 and the terminal complement pathway in a patient with homozygous C2 deficiency and systemic lupus erythematosus.
    Garred P; Mollnes TE; Thorsteinsson L; Erlendsson K; Steinsson K
    Scand J Immunol; 1990 Jan; 31(1):59-64. PubMed ID: 2300790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased activity of complement-mediated immune complex clearance in hemodialysis patients.
    Inagi R; Miyata T; Hong K; Pramoonjago P; Maeda K; Inoue K
    Clin Immunol Immunopathol; 1993 Sep; 68(3):333-9. PubMed ID: 8370184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
    Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
    Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus.
    Cines DB; Lyss AP; Reeber M; Bina M; DeHoratius RJ
    J Clin Invest; 1984 Mar; 73(3):611-25. PubMed ID: 6368583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement behavior in infectious mononucleosis: possible mechanisms for the prevention of immune complex injury.
    Charlesworth JA; Endre ZH; Pussell BA; Yasmeen D; Peake PW
    J Infect Dis; 1982 Apr; 145(4):505-13. PubMed ID: 7069231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deterioration of immune complex solubilization activity of serum by increased concentration of factor D.
    Miyata T; Inagi R; Oda O; Inoue I; Okada H; Miyama A; Nakashima I; Maeda K
    Nephron; 1991; 59(3):409-15. PubMed ID: 1758530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solubilization of immune precipitates by complement in the absence of properdin or factor D.
    Späth PJ; Pascual M; Meyer-Hänni L; Schaad UB; Schifferli JA
    FEBS Lett; 1988 Jul; 234(1):131-4. PubMed ID: 2968916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes.
    Swaak AJ; Hannema A; Vogelaar C; Boom FA; van Es L; van Aalst R; Statius van Eps LW
    Rheumatol Int; 1982; 2(4):161-6. PubMed ID: 6984977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes.
    Miletic VD; Hester CG; Frank MM
    J Immunol; 1996 Jan; 156(2):749-57. PubMed ID: 8543829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
    Fearon DT; Austen KF
    J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of sera of patients with systemic lupus erythematosus on artificial immune complexes.
    Bányai A; Szabó G; Csongor J; Sonkoly I; Szegedi G
    Acta Med Hung; 1985; 42(1-2):51-7. PubMed ID: 4034337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.